Reduced hypophagic effects of d-fenfluramine and the 5-HT2C receptor agonist mCPP in 5-HT1B receptor knockout mice

Psychopharmacology (Berl). 2004 Oct;176(1):39-49. doi: 10.1007/s00213-004-1864-0. Epub 2004 May 8.

Abstract

Rationale: The possible role of compensatory changes in 5-HT2C receptors in the reduced hypophagic action of d-fenfluramine in 5-HT1B knockout (KO) mice was assessed by comparing their response to d-fenfluramine and the 5-HT2C receptor agonist mCPP. In addition we measured 5-HT(2C/A) receptor binding in 5-HT1B KO and wild-type (WT) mice and examined the effects of 5-HT1B receptor antagonists on d-fenfluramine-induced hypophagia in WT mice.

Methods: Hypophagic responses to d-fenfluramine (1-30 mg/kg) and mCPP (1-5.6 mg/kg) were measured using a behavioural satiety sequence paradigm. The effects of the 5-HT1B receptor antagonists GR 127,935 and SB 224289 in opposing the hypophagic action of d-fenfluramine were evaluated in WT mice. The binding of [3H]-mesulergine was compared in the brains of both mouse strains.

Results: The hypophagic effects of moderate doses of d-fenfluramine and mCPP were attenuated in 5-HT1B KO mice. Pretreatment of WT mice with the 5-HT(1B/1D) receptor antagonist GR 127,935, or food-deprived WT mice with the 5-HT1B receptor antagonist SB 224289, did not reproduce the reduction in sensitivity to the effects of d-fenfluramine on feeding behaviour observed in 5-HT1B KO mice. Estimates of 5-HT2C receptor binding were similar in 5-HT1B KO and WT mice.

Conclusions: The hypophagic effect of d-fenfluramine in mice is unlikely to be mediated by the 5-HT1B receptor. Instead, the evidence suggests that an adaptive change in 5-HT2C receptor function occurs in 5-HT1B receptor KO mice and contributes to their reduced response to d-fenfluramine.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Binding Sites / drug effects
  • Binding Sites / physiology
  • Cerebral Cortex / drug effects
  • Cerebral Cortex / metabolism
  • Cerebral Cortex / ultrastructure
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Evaluation, Preclinical / methods
  • Eating / drug effects
  • Ergolines / administration & dosage
  • Ergolines / pharmacokinetics
  • Fenfluramine / administration & dosage
  • Fenfluramine / pharmacokinetics*
  • Genotype
  • Injections, Intraperitoneal
  • Injections, Subcutaneous
  • Isomerism
  • Mianserin / pharmacology
  • Mice
  • Mice, Knockout / genetics*
  • Piperazines / administration & dosage
  • Piperazines / pharmacokinetics*
  • Piperidones / administration & dosage
  • Piperidones / pharmacokinetics
  • Receptor, Serotonin, 5-HT1B / deficiency*
  • Receptor, Serotonin, 5-HT1B / genetics*
  • Receptor, Serotonin, 5-HT2A
  • Receptor, Serotonin, 5-HT2C / administration & dosage
  • Satiation / drug effects*
  • Satiation / physiology
  • Satiety Response / drug effects
  • Satiety Response / physiology
  • Serotonin 5-HT2 Receptor Agonists*
  • Species Specificity
  • Spiperone / pharmacology
  • Spiro Compounds / administration & dosage
  • Spiro Compounds / pharmacokinetics
  • Time Factors
  • Tritium
  • United Kingdom

Substances

  • Ergolines
  • Piperazines
  • Piperidones
  • Receptor, Serotonin, 5-HT1B
  • Receptor, Serotonin, 5-HT2A
  • Receptor, Serotonin, 5-HT2C
  • SB 22489G
  • Serotonin 5-HT2 Receptor Agonists
  • Spiro Compounds
  • Tritium
  • Mianserin
  • Fenfluramine
  • Spiperone
  • 1-(3-chlorophenyl)piperazine
  • mesulergine